BELFAST AND LONDON - Diaceutics PLC (AIM: LON:DXRX), a provider of technology and solutions for the pharmaceutical and biotech industries, announced the launch of its Pathology Engagement Liaisons (PEL) service. The company also reported securing a contract potentially worth up to $1.8 million over the next 12 months with a leading global pharmaceutical company.
The PEL service aims to enhance Diaceutics' existing PMx commercialization solution by facilitating the education and engagement of laboratory pathologists in the United States, specifically for pancreatic cancer testing. The service seeks to address the gap in direct engagement options between pharmaceutical companies and laboratories at scale.
According to the press release, the new service will leverage the DXRX platform and its laboratory network to promote biomarker testing and diagnostic education, which is expected to improve the adoption of biomarker tests and their implementation globally.
Susanne Munksted, Chief Precision Medicine Officer at Diaceutics, stated that the PEL service, through its use of the DXRX lab network in the US, would significantly impact patient lives by working with the pharmaceutical client to introduce new therapy options to patients in need.
The contract, which runs through the end of 2025, involves the deployment of PEL across the DXRX network laboratories in the US. The focus will be on pathologists conducting immunohistochemistry testing for pancreatic cancer patients, with the goal of enhancing biomarker education, testing awareness, and supporting the client's newly approved therapy. This, in turn, is expected to lead to better patient identification and clinical outcomes.
Although the PEL service is introduced as a standalone offering, it can also be integrated into Diaceutics' PMx commercialization solution, which is designed to optimize laboratory testing and patient recruitment for therapies. The addition of PEL is anticipated to increase the relevance of Diaceutics' services to therapy brands and boost the company's revenue per brand.
This announcement is based on a press release statement from Diaceutics PLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.